CD274 and neoplasm: Shifting tumor metabolism toward glycolysis by inhibiting tricarboxylic acid (TCA) cycle enzymes enhances the efficacy of anti-PD-L1 therapy, sensitizing tumors to immune-mediated killing and improving overall treatment response [78].